NextCure, Inc.

9000 Virginia Manor Rd. Suite 200
Beltsville
MD
20705
United States

Tel: (240)399-4900

Website: https://www.nextcure.com/

Email: Info@NextCure.com

Featured Employer
Show jobs for this employer

About NextCure, Inc.

NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. We view the immune system holistically and, rather than target one specific immune cell type, we focus on understanding biological pathways, the interactions of cells and the role each interaction plays in an immune response. Through our proprietary Functional, Integrated, NextCure Discovery in Immuno-Oncology, or FIND-IO, platform, we study various immune cells to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. We are focused on patients who do not respond to current therapies, patients whose cancer progresses despite treatment and patients with cancer types not adequately addressed by available therapies.

Cancer is a complex disease where cells in the tumor microenvironment promote tumor progression, immune evasion and suppression of anti-tumor immune responses. While therapies targeting inhibitory or immune checkpoint molecules have shown important success in many cancers, not all patients benefit from these therapies (non-responders), and many develop resistance after initial treatment. NextCure is identifying novel tumor-specific interactions and mechanisms of immune regulation to generate a sustainable product pipeline to address these patients in need.

NextCure brings significant experience and innovation in cancer immunology. The company’s FIND-IOTM technology provides a large repertoire of function-based screens and imparts a unique understanding of cell surface molecular interactions between immune and diseased cells. We are using this important knowledge to rapidly develop and advance novel biologics that impact suppressive myeloid cell populations, T cell subsets, and other cell populations within the tumor microenvironment to restore anti-tumor activity and improve clinical response rates and outcomes for patients.

Stock Symbol: NXTC

Business Spotlight - Nextcure

89 articles about NextCure, Inc.

  • NextCure, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, announced that it will present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13th.

  • NextCure, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, announced that it will participate in a fireside chat at the 19th Annual Morgan Stanley Global Healthcare Conference on September 9th at 12:30 pm Eastern time.

  • NextCure, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, reported second quarter 2021 financial results and provided a business update.

  • NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the initiation of a Phase 1/2 clinical trial for NC762, a humanized B7-H4 monoclonal antibody.

  • NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will participate in a fireside chat at the JMP Securities Life Sciences Conference

  • NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that clinical trial investigator, Martin Gutierrez, M.D., Director, Phase 1 Program and Co-Chair of Thoracic Oncology at Hackensack University Medical Center, will present a Trials in Progress poster for NC410 at the 2021 American Society of Clinical Oncologry

  • NextCure, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, reported first quarter 2021 financial results and provided a business update.

  • NextCure, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, announced that it will participate in a fireside chat at the BofA Securities 2021 Virtual Health Care Conference on May 12th at 2:00 pm Eastern time.

  • NextCure, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, announced that it will participate in a fireside chat at the 7th Annual Truist Securities Life Sciences Summit on May 5th at 2:40 pm Eastern time.

  • NextCure, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, presented preclinical and investigational new drug -enabling data for NC762 at the American Association for Cancer Research Annual Meeting 2021.

  • NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the 20 th Annual Needham Virtual Healthcare Conference on April 13 th at 12:45 pm Eastern time. A live audio webcast will be available through the Investors section of the company’s website at www

  • NextCure, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, reported fourth quarter and full year 2020 financial results and provided a business update.

  • NextCure, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, announced that it will host a Virtual R&D Update Event at 5:00 p.m. ET on Thursday, March 4.

  • NextCure, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, announced that it will host a Virtual R&D Update Event at 5:00 p.m. ET on Thursday, March 4.

  • NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today provided an update on the clinical trial program for NC318, its first-in-class immunomedicine against Siglec15 (S15), a novel immunomodulatory target. “As we continue to review and analyze the available clinical and laboratory data on

  • NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will participate in a fireside chat at the Piper Sandler Virtual 32nd Annual Healthcare Conference on December 1st.

  • NextCure, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, reported third quarter 2020 financial results and provided a business update.

  • NextCure, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, announced that it will present at the Morgan Stanley Virtual 18th Annual Global Healthcare Conference on September 15th at 4:15 pm Eastern time.

  • NextCure, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, reported second quarter 2020 financial results and provided a business update.

  • NextCure, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, announced that it will present at the BTIG Virtual Biotechnology Conference on August 11th at 9:30 am Eastern time.